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Summary
Objective:  Recently,  de  novo  SCN8A  missense  mutations  have  been  identiﬁed  as  a  rare  dominant
cause of  epileptic  encephalopathies  (EIEE13).  Functional  studies  on  the  ﬁrst  described  case
demonstrated  gain-of-function  effects  of  the  mutation.  We  describe  a  novel  de  novo  mutation
of SCN8A  in  a  patient  with  epileptic  encephalopathy,  and  functional  characterization  of  the
mutant protein.encing  was  used  to  discover  the  variant.  We  generated  a  mutantPatch-clamp Design:  Whole  exome  sequ
cDNA, transfected  HEK293  cells,  and  performed  Western  blotting  to  assess  protein  stability.  To
study channel  functional  properties,  patch-clamp  experiments  were  carried  out  in  transfected
neuronal  ND7/23  cells.
Results:  The  proband  exhibited  seizure  onset  at  6  months  of  age,  diffuse  brain  atrophy,  and
more profound  developmental  impairment  than  the  original  case.  The  mutation  p.Arg233Gly
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in  the  voltage  sensing  transmemb
both parents.  This  mutation  resu
as well  as  reduced  sodium  curren
slow ramp  stimulus,  though  this  d
temperatures.
Conclusion:  The  new  de  novo  SC
protein with  reduced  channel  ac
ﬁrst SCN8A  mutation  in  epileptic  e
Nav1.6 is  expressed  in  both  excit
function of  Nav1.6  Arg223Gly  on  i
this patient.
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mong  the  known  epilepsy  genes,  brain-expressed  voltage-
ated  sodium  channels  are  currently  the  most  clinically
elevant,  with  a  large  number  of  mutations  detected  in
atients  suffering  from  various  epileptic  disorders,  the
ajority  in  SCN1A  (Mulley  et  al.,  2005),  smaller  numbers  in
CN2A  (Shi  et  al.,  2012),  and  a  few  in  other  channels  (Meisler
t  al.,  2010).  The  association  of  voltage-gated  sodium
hannels  with  epilepsy  displays  both  clinical  and  genetic
eterogeneity.  Dominant  mutations  in  both  SCN1A  and
CN2A  have  been  found  in  severe  as  well  as  milder  epilep-
ic  disorders:  MIM607208  and  MIM604403,  and  MIM613721
nd  MIM607745  respectively.  A  strong,  yet  incomplete,
orrelation  exists  between  mutation  type  (i.e.  missense
r  nonsense)  and  the  corresponding  epilepsy  phenotype
Scheffer  et  al.,  2009).  For  example,  nonsense  mutations
n  SCN1A  are  predominantly  found  in  Dravet  syndrome
atients,  which  predict  a  loss  of  function  of  one  allele  and
aploinsufﬁciency  as  the  main  disease  mechanism.  On  the
ther  hand,  missense  mutations  are  predominantly  found  in
EFS+  patients,  suggesting  a  gain  of  function  effect  under-
ying  this  milder  form  of  epilepsy.  The  variety  in  effects
f  mutations  in  these  sodium  channel  genes  underscores
he  importance  of  careful  phenotype  versus  genotype  and
olecular  phenotype  comparisons  to  elucidate  the  clini-
al  relevance  of  sodium  channel  mutations  (Meisler  and
earney,  2005).
In  2012,  the  de  novo  mutation  p.Asn1768Asp  in  SCN8A
encoding  Nav1.6)  was  reported  in  a  child  with  infantile
pileptic  encephalopathy  (EE)  and  SUDEP  (Veeramah  et  al.,
012).  The  authors  showed  that  the  functional  effect  of  the
utation,  an  increase  in  persistent  current,  was  consistent
ith  a  dominant,  gain-of-function  phenotype  (Veeramah
t  al.,  2012),  suggesting  that  gain-of-function  mutations  of
CN8A  can  underlie  EE.  Earlier,  an  inherited  loss  of  function
utation  caused  by  a  2  bp  deletion  (Pro1719ArgfsX6)  (Supp.
ig.  A1)  had  been  reported  as  a  possible  cause  for  cere-
ellar  ataxia  and  cognitive  problems  (Meisler  and  Kearney,
005;  Trudeau  et  al.,  2006).  Recently,  seven  additional
otentially  pathogenic  mutations  in  SCN8A  were  reported
n  patients  with  intellectual  disability  and  seizures  (Carvill
t  al.,  2013;  Epi4K-Consortium,  2013;  Rauch  et  al.,  2012;
aher  et  al.,  2013)  (Supp.  Fig.  A1).  Four  were  demonstrated
o  be  de  novo, one  was  inherited  from  an  asymptomatic
osaic  father,  and  for  two  the  inheritance  was  not  known.
T
a
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rane  segment  D1S4  was  present  in  the  proband  and  absent  in
lts  in  a  temperature-sensitive  reduction  in  protein  expression
t  amplitude  and  density  and  a  relative  increased  response  to  a
id  not  result  in  an  absolute  increased  current  at  physiological
N8A  mutation  is  clearly  deleterious,  resulting  in  an  unstable
tivity.  This  differs  from  the  gain-of-function  attributes  of  the
ncephalopathy,  pointing  to  heterogeneity  of  mechanisms.  Since
atory  and  inhibitory  neurons,  a  differential  effect  of  a  loss-of-
nhibitory  interneurons  may  underlie  the  epilepsy  phenotype  in
erved.
ll  reported  de  novo  mutations  in  patients  with  epileptic
ncephalopathy  so  far  are  missense  mutations  changing  a
onserved  amino  acid,  but  no  further  electrophysiological
nalyses  have  been  published  (O’Brien  and  Meisler,  2013).
hese  observations  establish  dominant  missense  mutations
n  SCN8A  as  a cause  of  EE  (EIEE13),  but  functional  charac-
erization  of  additional  mutations  is  required  to  determine
he  general  disease  mechanism.
We  detected  a  de  novo  mutation  in  SCN8A  (c.667A  >  G)  in
 girl  with  epileptic  encephalopathy  and  secondary  micro-
ephaly.  In  this  paper,  we  report  a  clinical  description  of
ur  new  case  and  functional  properties  of  the  new  mutation
Nav1.6-p.Arg223Gly)  and  compared  them  to  the  previously
haracterized  de  novo  mutation  (Veeramah  et  al.,  2012).
ethods
utation  detection
hole  exome  sequencing  was  performed  on  genomic  DNA
rom  both  the  parents  and  the  affected  child  from  six  trios.
aboratory  and  bioinformatics  procedures  were  carried  out
s  previously  described  (Nijman  et  al.,  2010).  Candidate  de
ovo  variants  that  were  predicted  to  alter  protein  func-
ion  were  sequenced  in  fresh  DNA  aliquots  with  Sanger
equencing.  We  also  looked  for  homozygous  or  compound
eterozygous  mutations  that  could  be  a  plausible  cause  of
he  disorder.
eneration  and  expression  of  the  mutant  cDNA
he  c.667A  >  G  nucleotide  mutation  was  introduced  into  the
etrodotoxin  (TTX)-resistant  derivative  of  the  murine  Nav1.6
DNA  clone  Nav1.6R as  previously  described  (Sharkey  et  al.,
009).  Mouse  Scn8a  is  an  appropriate  model  for  human
CN8A,  since  the  human  and  mouse  proteins  are  99%  iden-
ical  in  amino  acid  sequence  (Plummer  et  al.,  1998),  and
n  vivo  expression  of  the  human  epileptic  encephalopathy
utation  N1768D  in  the  mouse  results  in  a  similar  pheno-
ype  of  early  onset  convulsive  seizures  and  SUDEP  (Jones
nd  Meisler,  2014)(and  unpublished  observations  by  MHM).
he  6-kb  open  reading  frame  was  sequenced  to  conﬁrm  the
bsence  of  additional  mutations.
To  assess  protein  stability,  mutant  and  wildtype  cDNAs
ere  transfected  into  HEK293  cells  which  are  well  suited
ith  
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wCharacterization  of  a  de  novo  SCN8A  mutation  in  a  patient  w
for  Western  blot  analysis  because  of  the  lack  of  endoge-
nous  sodium  channel  protein.  After  culture  for  24  h  at  37 ◦C,
cells  were  harvested  and  divided  in  half  for  extraction  of
RNA  and  protein.  To  control  for  transfection  efﬁciency  the
abundance  of  the  Nav1.6  transcript  was  analysed  by  qRT-
PCR,  as  previously  described  (Lenk  et  al.,  2011).  Transfected
cells  matched  for  abundance  of  the  Nav1.6  transcript  were
lysed  in  RIPA  buffer  and  aliquots  containing  30  g  of  protein
were  incubated  with  Laemmli  sample  buffer  for  20  min  at
37 ◦C,  electrophoresed  through  4—15%  acrylamide  gradient
gels  (Criterion),  and  immunostained  with  rabbit  polyclonal
anti-Nav1.6  (Alomone  ASC-009,  1:100)  and,  as  an  inter-
nal  control,  mouse  monoclonal  anti-FIG4  (NeuroMab  clone
N202/7).
Functional  characterization  of  the  mutant  channel
Channel  activity  was  evaluated  by  co-transfection  of  the
eGFP  cDNA  together  with  mutant  or  wildtype  Nav1.6  murine
cDNAs  into  the  dorsal  root  ganglion  (DRG)  neuron-derived
cell  line  ND7/23  as  previously  described  (Sharkey  et  al.,
2009;  Veeramah  et  al.,  2012).  ND7/23  neuronal  cells  sup-
port  larger  Nav1.6  currents  than  HEK293  cells,  and  have
been  our  preferred  expression  system  for  voltage-clamp
experiments.  In  the  presence  of  300  nM  TTX,  endogenous
sodium  currents  are  blocked  and  currents  derived  from
the  transfected  Nav1.6R clones  can  be  studied  in  isola-
tion.  Forty-eight  hours  after  transfection,  cells  with  robust
green  ﬂuorescence  were  selected  for  recording.  For  one  set
of  experiments,  transfected  ND7/23  cells  were  incubated
overnight  at  30 ◦C  instead  of  37 ◦C  prior  to  recording.
Whole-cell  voltage-clamp  recordings  were  performed
and  analysed  as  previously  described  (Veeramah  et  al.,  2012)
(and  supplement).  Data  were  analysed  using  Clampﬁt  10.2
(Molecular  Devices)  and  Origin  8.5  Pro  (Microcal  Software).
The  Mann—Whitney  nonparametric  test  was  used  to  analyse
current  density  data.  Student  t-test  was  used  to  assess  the
statistical  signiﬁcance  in  characteristics  of  WT  and  NaV1.6R-
Arg223Gly  mutant  channels.
Results
Mutation  detection
Sequencing  coverage  was  between  50  and  100× in  parents
and  proband,  with  percentage  of  insufﬁciently  covered  tar-
get  sequences  ranging  from  7%  in  the  proband  to  13%  in
the  father.  The  patient  carried  a  de  novo  variant  in  SCN8A:
chr12:52082594  (hg19);  c.667A  >  G,  p.Arg223Gly.  The  muta-
tion  alters  the  second  arginine  residue  in  the  voltage-sensing
transmembrane  segment  S4  of  domain  I,  and  is  highly  con-
served  across  species  (Supp.  Fig.  A2).
Description  of  patient
The  patient  carrying  the  p.Arg223Gly  mutation  is  the  daugh-
ter  of  healthy  unrelated  parents,  and  was  3  years  old  at  the
latest  investigation  in  2013.  She  was  born  after  an  unevent-
ful  pregnancy  of  41  weeks.  At  age  6  months,  she  developed
clustered  episodes  of  eye  rolling  and  mouthing  movements,
o
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ithin  days  evolving  into  clusters  of  ﬂexor  spasms,  occurring
aily  with  increasing  frequency.  The  EEG  showed  an  epilep-
ic  encephalopathy  and  valproic  acid  was  started.  After  a
ew  days,  the  EEG  evolved  to  a  hypsarhythmia  and  treat-
ent  with  adrenocorticotropic  hormone  (ACTH)  therapy  was
tarted,  but  unsuccessful,  and  treatment  with  vigabatrin
as  initiated.  Seizure  severity  and  duration  decreased  for  a
ew  days,  but  thereafter  increased  again,  despite  treatment
ith  pyridoxal  phosphate,  nitrazepam,  midazolam,  leve-
iracetam  and  diphantoin.  Because  of  the  risk  of  respiratory
nsufﬁciency  and  on-going,  frequent  seizures  characterized
y  eye  rolling,  tachypnoea  and  tachycardia,  the  patient
as  admitted  to  the  intensive  care  unit  for  ventilation  and
reatment  with  subsequently  phenobarbital,  topiramate,
ropofol,  thiopental,  methylprednisolone  and  magnesium.
 ketogenic  diet  was  started.  Hereafter  she  continued  to
ave  brief  tonic  and  clonic  seizures  occurring  2  to  3  times  a
ay.
At  age  six  months,  when  seizures  were  ﬁrst  observed,
evelopment  was  slightly  delayed.  Seizure  onset  was  associ-
ted  with  developmental  regression.  At  age  three  years  she
howed  severe  psychomotor  retardation:  she  was  not  able  to
it  without  support  and  had  no  speech.  Head  circumference
as  normal  at  seizure  onset  (−1  SD)  but  showed  progressive
ecline  and  at  age  2.5  years  it  was  −3 SD.  Comorbid  prob-
ems  were  central  precocious  puberty  diagnosed  at  age  19
onths,  and  constipation.
After  the  intensive  care  unit  stay,  EEG  showed  multifocal
pileptiform  discharges  and  background  slowing.  Magnetic
esonance  imaging  (MRI)  of  the  brain  was  initially  normal
ut  at  age  9  months  showed  diffuse  brain  atrophy,  includ-
ng  slight  atrophy  of  the  cerebellum,  and  interruption  of
yelination.
The  clinical  characteristics  of  our  patient  are  summarized
n  Supplemental  Table  A1.
unctional  characterization  of  the  mutant  channel
he  p.Arg223Gly  mutation  was  introduced  into  the  cDNA
lone  mNaV1.6R as  described  in  Methods.  Wildtype  and
utant  plasmids  were  transfected  into  the  DRG-derived
euronal  cell  line  ND7/23  and  whole-cell  voltage-clamp
ecordings  were  performed  (Fig.  1).  We  used  the  mouse
av1.6  clone  in  the  present  study  to  facilitate  comparison
ith  our  previous  characterization  of  the  ﬁrst  SCN8A  human
utation  (Veeramah  et  al.,  2012).
Examples  of  inward  currents  recorded  by  this  proto-
ol  are  shown  in  Fig.  1A.  With  standard  culture  conditions
transfected  cells  incubated  at  37 ◦C),  the  peak  current  den-
ity  generated  by  the  mutant  channel  (−14.3  ±  3.7  pA/pF,
 =  15)  was  greatly  reduced  in  comparison  with  that  of
he  wildtype  channel  (−69  ±  30  pA/pF,  n  =  14,  p  =  0.047)
Fig.  1B).
One  possible  cause  of  reduced  current  amplitude  would
e  reduced  levels  of  channel  protein  due  to  misfolding  at
7 ◦C  (Sharkey  et  al.,  2009).  To  evaluate  this  possibility,
e  transfected  HEK293  cells  and  examined  the  abundance
f  mutant  and  wildtype  protein  by  Western  blot.  To  con-
rol  for  variation  in  transfection  efﬁciency,  we  isolated
NA  from  transfected  cells  and  determined  the  abundance
f  the  Nav1.6  transcript  by  qRT-PCR.  Transfections  with
1514  C.G.F.  de  Kovel  et  al.
Fig.  1  Functional  characterization  of  the  p.Arg223Gly  mutant  in  Nav1.6.  Neuronal  ND7/23  cells  were  transfected  with  wildtype
or mutant  Nav1.6  cDNA.  (A)  Cells  were  grown  overnight  at  the  normal  temperature  of  37 ◦C  or  reduced  temperature  of  30 ◦C  and
recorded at  room  temperature.  Superimposed  traces  recorded  in  response  to  the  activation  stimulation  protocol  (100  msec  duration
pulses) are  shown.  (B)  Peak  currents  were  normalized  for  cell  capacitance  and  averaged  to  obtain  the  expressed  current-density  for
cells expressing  mNav1.6r-WT  (light  grey,  n  =  14  at  37 ◦C,  9  at  30 ◦C)  or  mNav1.6r-Arg223Gly  (dark  grey,  n  =  15  at  37 ◦C,  12  at  30 ◦C)
grown at  37 ◦C  or  30 ◦C  overnight.  (C)  Activation  G—V  curves  were  normalized  and  averaged  as  described  in  ‘Methods’.  (D)  Responses
to the  fast-inactivation  protocol  are  analysed  to  obtain  the  voltage-dependence  of  fast-inactivation  as  described  in  ‘Methods’.  Error
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(ars are  standard  error  of  the  mean  (SEM).  The  averages  of  the  n
rown at  37 ◦C  or  30 ◦C  were  not  signiﬁcantly  different  (C).  See
omparable  transcript  level  were  compared  by  Western
lotting.  The  amount  of  mutant  protein  was  consistently
educed  in  comparison  with  wildtype  channel  in  four  inde-
endent  transfection  experiments  (Fig.  3  and  Supplemental
ig.  A3).  The  amount  of  mutant  channel  in  50  g  of  trans-
ected  cell  extract  was  comparable  to  the  level  of  wildtype
rotein  in  10  g  of  extract,  suggesting  that  the  stability  of
he  mutant  protein  is  reduced  by  80%  (Supplemental  Fig.  A3,
eft  panel).
To  compensate  for  the  defect  in  expression  of  mutant
hannel  protein  at  37 ◦C,  we  cultured  transfected  ND7/23
ells  at  30 ◦C.  This  resulted  in  signiﬁcant  recovery  of  channel
unction  (Fig.  1A).  At  30 ◦C,  the  peak  current  density  mea-
ured  from  cells  transfected  with  p.Arg223Gly  (−122  ±  67
A/pF,  n  =  12)  was  approximately  one  third  of  the  current
ensity  of  wildtype-transfected  cells  (−370  ±  165  pA/pF,
 =  9,  p  =  0.014)  (Fig.  1B).
The  voltage-dependence  of  activation  and  fast-nactivation  were  examined  by  transforming  the  peak
urrent  versus  voltage  (I—V)  curves  into  conductance
ersus  voltage  (G—V)  curves.  The  Boltzmann  ﬁts  for  both
ctivation  and  fast-inactivation  were  derived  for  each  cell
D
W
wlized  G—V  curves  for  activation  for  Arg223Gly  and  WT  channels
lement  for  data.
ndividually.  The  averages  of  the  normalized  G—V  curves  for
ctivation  for  p.Arg223Gly  and  WT  channels  grown  at  37 ◦C
r  30 ◦C  were  not  signiﬁcantly  different  (Fig.  1C).  Growth
t  37 ◦C  versus  30 ◦C  did  not  signiﬁcantly  affect  the  average
f  the  ﬁts  for  fast-inactivation  (Fig.  1D).
We  evaluated  the  response  of  wildtype  and  mutant  chan-
els  to  slow  ramp  depolarisations.  These  experiments  were
arried  out  at  30 ◦C  to  stabilize  the  mutant  protein.  To
ermit  comparisons  between  cells,  the  response  was  nor-
alized  to  the  peak  inward  current  recorded  during  the
ctivation  I—V  protocol.  The  averaged  response  of  mutant
nd  wildtype  channels  is  shown  in  Fig.  2.  The  peak  of  the
low  ramp  response  of  cells  expressing  p.Arg223Gly  aver-
ged  3.5  ±  0.7%  (n  =  11),  which  is  a  3-fold  increase  over  the
verage  ramp  response  of  1.0  ±  0.2%  in  WT-expressing  cells
n  = 5,  p  =  0.004).iscussion
e  describe  a  patient  with  epileptic  encephalopathy
ho  carries  a  de  novo  missense  variant  in  SCN8A
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Fig.  2  Enhanced  ramp  activity  of  Nav1.6  resulting  from  the
p.Arg223Gly  mutation.  Data  traces  recorded  in  response  to
a slow  ramp  stimulus  of  −120  mV  to  +20  mV  over  600  ms  are
ﬁltered  to  200  Hz  and  normalized  to  peak  I—V  current.  The
normalized  ramp  traces  are  averaged  together  for  cells  express-
ing Nav1.6-WT  (black  line,  n  =  5)  or  Nav1.6-Arg223Gly  channels
(grey line,  n  =  11).  Selected  points  are  plotted  as  mean  ±  SEM  to
indicate  the  variance  of  the  averages.  (For  interpretation  of  the
Fig.  3  The  p.Arg223Gly  mutation  reduces  the  stability  of
the Nav1.6  channel  protein.  HEK293  cells  were  transfected
with mutant  or  wildtype  Nav1.6  cDNA  and  cultured  for  24  h
at 37  degrees.  Aliquots  of  cell  extracts  containing  30  g  pro-
tein were  subjected  to  electrophoresis  on  4—15%  gradient  gels
and transferred  to  a  nitrocellulose  ﬁlter  as  described  in  ‘Meth-
ods’.  Nav1.6  was  detected  with  a  rabbit  polyclonal  antibody
(Alomone).  As  a  control  for  loading  and  transfer  efﬁciency,
the ﬁlter  was  washed  and  the  endogenous  FIG4  protein  was
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preferences  to  color  in  this  ﬁgure  legend,  the  reader  is  referred
to the  web  version  of  this  article.)
(Nav1.6  p.Arg223Gly)  and  compared  clinical  phenotype
and  biophysical  properties  of  the  mutation  with  a  previ-
ous  described  mutation  (Veeramah  et  al.,  2012).  The  two
patients  exhibit  similar  clinical  features  including  severe
epileptic  encephalopathy  with  onset  at  age  6  months.  Unlike
in  Dravet  syndrome,  initial  seizures  showed  no  association
with  fever  or  illness.  Initial  seizure  frequency  was  very  high
in  both  patients.  However,  the  clinical  progression  is  more
severe  in  the  current  patient,  since  at  the  age  of  3  years  the
original  patient  was  ambulatory  with  less  cognitive  impair-
ment.  In  both  patients,  the  clinical  picture  includes  spasms,
albeit  at  different  ages,  and  developmental  delay  with  poor
outcome  (Supp.  Table  1A).  Comparison  of  the  novel  Nav1.6
Arg223Gly  mutation  with  the  previously  described  Nav1.6
Asn1768Asp  demonstrated  that  the  effects  of  the  two  muta-
tions  are  divergent  in  several  respects.  First,  the  Arg223Gly
current  amplitude  was  only  about  20%  that  of  the  wild  type
channels  when  cells  were  incubated  at  the  physiological
temperature  of  37 ◦C.  Second,  Arg223Gly  mutant  channels
do  not  produce  a  persistent  current  or  manifest  incom-
plete  inactivation  as  observed  in  Nav1.6  Asn1768Asp  current
recordings.  Third,  at  the  permissive  temperature  of  30 ◦C
we  observed  a  3-fold  increase  in  the  ramp  current  normal-
ized  to  peak  current  for  Nav1.6  Arg223Gly,  similar  to  that
observed  for  Nav1.6  Asn1768Asp.  However,  when  expressed
in  terms  of  absolute  current  levels,  there  was  a  signiﬁcant
reduction  in  ramp  current  of  the  mutant  channel  even  at  the
permissive  temperature,  suggesting  that  this  increase  may
not  be  biologically  relevant.  These  observations  argue  that  a
loss-of-function  mutation  in  SCN8A  may  underlie  the  seizure
disorder  in  this  patient
At  37 ◦C  peak-current  density  was  signiﬁcantly  reduced  in
Nav1.6  Arg223Gly,  which  may  be  explained  by  the  reduced
protein  stability  of  the  mutant  relative  to  WT.  At  30 ◦C,
i
1
a
vmmunostained  with  a  mouse  monoclonal  antibody  (NeuroMab).
u, mutant;  Wt,  wildtype;  Un,  untransfected;  o,  gel  origin.
eak-currents  were  partially  recovered,  an  effect  seen  in
ther  ion  channel  mutants,  which  may  make  gain  of  function
ffects  more  apparent  (Cestele  et  al.,  2013).  Though  37 ◦C  is
he  physiological  temperature  for  humans,  in  vitro  systems
ay  display  a  higher  instability  at  these  temperatures  than
he  in  vivo  situation  owing  to  their  artiﬁcial  nature.  Further-
ore,  in  vivo  compensation  for  the  reduced  SCN8A  activity
ight  also  contribute  to  neuronal  hyperexcitability  (Cestele
t  al.,  2013;  Vega  et  al.,  2008).  However,  unlike  the  Nav1.1
utation  referred  to  above  (Cestele  et  al.,  2013)  and  the
olding-defective  Nav1.6  mutation  in  ataxia3  mice  (Sharkey
t  al.,  2009),  the  rescue  of  p.Arg223Gly  at  the  lower  tem-
erature  did  not  uncover  a  robust  gain-of-function  change
hat  could  explain  the  hyperexcitability  phenotype.
Multiple  biophysical  mechanisms  can  contribute  to  the
roduction  of  the  ramp  current  (Estacion  and  Waxman,
013).  Although  window  currents  generated  within  the  volt-
ge  domain  delineated  by  the  Boltzmann’s  ﬁts  for  activation
nd  inactivation  may  contribute  to  ramp  currents,  other
roperties,  for  example  the  rate  of  entry  into  closed  state
nactivation,  may  have  a  major  effect  (Cummins  et  al.,
998).  Thus,  an  increased  ramp  current  may  occur  in  the
bsence  of  an  effect  on  the  voltage-dependence  of  inacti-
ation.  At  the  cellular  level,  a  signiﬁcant  increase  in  ramp
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urrents  may  enhance  the  activity  of  the  mutant  channel  in
he  range  of  subthreshold  depolarisations  for  wildtype  chan-
els,  and  thus  enhance  the  probability  of  neurons  reaching
he  threshold  for  action  potential  ﬁring.  However,  although
e  report  an  increase  in  the  ramp  current  normalized  to  the
eak  current,  we  note  that  the  large  and  signiﬁcant  reduc-
ion  in  the  peak  current  density  of  the  Arg223Gly  channels,
eaching  only  20%  that  of  wildtype  channels  at  physiological
emperatures,  suggests  that,  in  terms  of  absolute  currents,
he  mutant  channel  may  only  produce  up  to  60%  of  the  ramp
urrent  of  the  wildtype  channel.
Mutations  in  SCN1A  cause  the  epileptic  encephalopathy
ravet  syndrome  (MIM  607208).  Most  of  the  pathogenic
CN1A  mutations  cause  loss-of-function  (Claes  et  al.,  2009).
utations  in  SCN2A  causing  epileptic  encephalopathy  (MIM
613721)  include  both  loss-  and  gain-of-function  mutations
Ogiwara  et  al.,  2009).  The  previously  described  SCN8A
utation  was  a  gain-of-function  mutation  (Veeramah  et  al.,
012),  and  all  of  the  described  SCN8A  mutations  thus  far
ave  been  missense  mutations  which  could  cause  gain  or  loss
f  function.  The  alpha  subunits  of  different  sodium  chan-
els  have  distinct  intracellular  and  anatomical  distributions
n  the  brain.  In  a  recent  review,  Oliva  et  al.  (2012)  com-
ared  the  role  of  these  voltage-gated  sodium  channels.  The
hree  major  subunits,  SCN1A, SCN2A, and  SCN8A, are  all
xpressed  in  excitatory  neurons  (Liu  et  al.,  2013;  Ogiwara
t  al.,  2013;  Oliva  et  al.,  2012).  SCN1A  and  SCN8A  are  also
xpressed  in  inhibitory  neurons  (Cheah  et  al.,  2012;  Dutton
t  al.,  2012;  Lorincz  and  Nusser,  2008;  Ogiwara  et  al.,  2013).
ll  three  channel  proteins  are  present  in  speciﬁc  domains  of
he  axon  initial  segment,  where  SCN2A  may  contribute  to
ack  propagation  to  the  soma  and  dendrites  (Oliva  et  al.,
012,  2014).  SCN8A  encoded  Nav1.6  is  concentrated  in  the
istal  portion  of  the  axon  initial  segment  (AIS)  and  in  the
odes  of  Ranvier  (Lorincz  and  Nusser,  2008;  Royeck  et  al.,
008;  Van  Wart  and  Matthews,  2006)  and  is  also  found  at
ower  abundance  in  the  soma  and  dendrites  (Lorincz  and
usser,  2008,  2010).  SCN8A  has  a  lower  threshold  of  acti-
ation  than  SCN2A  (Royeck  et  al.,  2008;  Rush  et  al.,  2005),
nd  plays  an  important  role  in  action  potential  initiation
Hu  et  al.,  2009).  Though  strong  similarities  exist  between
hese  closely  related  channels,  there  are  important  func-
ional  differences.  Mutations  in  all  three  channels  can  result
n  epilepsy,  but  the  biophysical  mechanisms  are  probably
ifferent  and  need  careful  examination.
We  previously  demonstrated  that  a  gain-of-function
utation  of  Nav1.6  from  a  subject  with  infantile-onset
pilepsy  enhances  persistent  sodium  current  and  shifts
ast-inactivation  in  a  depolarizing  direction,  producing
yperexcitability  and  PDS-like  complexes  in  pyramidal  hip-
ocampal  neurons  (Veeramah  et  al.,  2012).  Studies  on
cn8amed mice  lacking  functional  Nav1.6  channels  demon-
trate  reduced  excitability  of  CA1  pyramidal  neurons
Royeck  et  al.,  2008).  Up-regulation  of  Nav1.6  by  the  splic-
ng  factor  Celf4,  which  is  expressed  in  excitatory  but  not
nhibitory  neurons,  has  been  linked  to  seizures  (Sun  et  al.,
013).  Nevertheless,  loss-of-function  Nav1.6  might  lead  to
ifferential  impact  on  inhibitory  neurons,  where  Nav1.6  is
nown  to  be  present  at  the  axon  initial  segment  (Lorincz
nd  Nusser,  2008),  possibly  affecting  inhibitory  neurons  more
han  excitatory  neurons  within  an  epileptogenic  circuit.  The
eterozygous  Scn8a-null  mouse  has  in  fact  been  reported
S
f
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o  manifest  spontaneous  spike-wave  discharges  consistent
ith  absence  epilepsy  (Papale  et  al.,  2009).  Variation  in
ther  ion  channels  may  also  inﬂuence  the  disease  phenotype
n  an  individual  patient.  Thus  a  loss-of-function  mutation
n  Nav1.6,  as  shown  in  this  study,  might  yield  an  epileptic
henotype.
It remains  to  be  determined  whether  pure  loss-of-
unction  mutations  in  human  SCN8A  are  a  common  cause
f  epileptic  encephalopathy.  It  is  clear  that  heterozy-
ous  loss-of-function  of  SCN8A  is  not  invariably  associated
ith  epilepsy.  For  example,  the  frameshift  mutation
.Pro1719Arg*6  segregates  in  a  family  with  mild  cogni-
ive  impairment  but  no  history  of  seizures  (Trudeau  et  al.,
006).  In  addition,  the  heterozygous  protein  truncation
ariant  P.Gly656Arg  is  present  in  14/5300  individuals  in
he  exome  variant  server  database  (Exome  Variant  Server,
HLBI  GO  Exome  Sequencing  Project  (ESP),  Seattle,  WA
URL:  http://evs.gs.washington.edu/EVS/)  [March,  2014
ccessed].)  which  does  not  include  individuals  with  early
nset  neurological  disorders.  The  effect  of  loss-of-function
utations  is  likely  to  be  inﬂuenced  by  genetic  background
f  each  individual  genome  (Oliva  et  al.,  2014),  in  particular
y  variation  in  other  channel  genes.
The  patient  described  here  supports  recent  reports
hat  de  novo  mutations  of  SCN8A  constitute  a  recurrent
ause  of  severe,  early  onset  epileptic  encephalopathy.  The
unctional  data  demonstrate  that  the  SCN8A-p.Arg223Gly
utation  in  this  mutation  is  deleterious,  although  the
recise  mechanism  of  epileptogenesis  is  not  completely
stablished.  Functional  characterization  of  additional  vari-
nts  in  addition  to  the  two  reported  to  date  will  contribute
o  understanding  the  genotype—phenotype  correlations  and
he  mechanisms  underlying  this  devastating  disorder.
ote added in proof
hile  this  paper  was  under  review,  a  paper  describing  func-
ional  characterization  of  mutation  p.Thr767Ile  in  SCN8A,
hich  had  also  been  found  in  a  patient  with  epileptic
ncephalopathy,  came  out.  This  mutation  shows  different
unctional  characteristics  than  the  mutation  described  here
Estacion  et  al.,  2014).
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